ArticleCells2020
High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series.
Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review.British journal of cancer · 2025Pooled it
- Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial.Cancer · 2025Trial
- Real-World Experience of Efficacy and Tolerability of Continuous Infusion Ifosfamide for Advanced Soft Tissue and Bone Sarcoma Patients: A Single Centre Retrospective Cohort.Cancer medicine · 2026Article
- Long-term benefit from high-dose ifosfamide in sarcoma depends on sustained prior control and timely intervention: a machine learning analysis.Journal of cancer research and clinical oncology · 2026Article
- MicroRNA signatures in osteosarcoma: diagnostic insights and therapeutic prospects.Molecular and cellular biochemistry · 2025Review
- Central memory-enriched Vγ9Vδ2 γδ T cells via TGF-β expansion demonstrate enhancedFrontiers in immunology · 2025Article
- Case Report: Malignant transformation of maxillary giant cell tumor of bone from EURACAN reference center.Frontiers in oncology · 2025Article
- Article
- Beneficial effect of heat-killed Lactiplantibacillus plantarum L-137 on intestinal barrier function of rat small intestinal epithelial cells.Scientific reports · 2024Article
- Enhancement of the therapeutic efficacy of the MAP regimen using thiamine pyrophosphate-decorated albumin nanoclusters in osteosarcoma treatment.Bioengineering & translational medicine · 2023Article
- Lung metastasectomy for osteosarcoma in children, adolescents, and young adults: proof of permanent cure.Tumori · 2023Article
- Engineered biomaterial delivery strategies are used to reduce cardiotoxicity in osteosarcoma.Frontiers in pharmacology · 2023Review
- Neoadjuvant Chemotherapy and Expandable Prosthesis Reconstruction to Treat Osteosarcoma around the Knee in Children.Orthopaedic surgery · 2023Article
- Turmeronols (A and B) fromBioscience of microbiota, food and health · 2023Article
- Chemoresistance-Related Stem Cell Signaling in Osteosarcoma and Its Plausible Contribution to Poor Therapeutic Response: A Discussion That Still Matters.International journal of molecular sciences · 2022Review
- Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre.International journal of molecular sciences · 2022Review
- Efficacy of ifosfamide combined with liposome doxorubicin on osteosarcoma and its effects on serum IL-10, TNF-α, and IFN-γ in patients with osteosarcoma.American journal of translational research · 2022Article
- Investigation of Ifosfamide Toxicity Induces Common Upstream Regulator in Liver and Kidney.International journal of molecular sciences · 2021Article
- Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies.Cancers · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.